Intravenous ferric carboxymaltose in patients with heart failure and iron deficiency: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis
Intravenous FCM in HF patients is associated with reduced risk of adverse cardiovascular events and improved functional capacity. Further trials are needed to clarify its long-term survival impact.
Authors
- Rohma Zia (ORCID: https://orcid.org/0000-0002-7644-448X)
- Jamal S. Rana (ORCID: https://orcid.org/0000-0002-8222-3958)
- Muhammad Abdullah Naveed
- Faizan Ahmed (ORCID: https://orcid.org/0000-0002-2760-6892)
- Eeshal Zulfiqar (ORCID: https://orcid.org/0009-0009-6346-6629)
- Mushood Ahmed (ORCID: https://orcid.org/0000-0001-9872-8224)
- Hadiah Ashraf
- Tallal Mushtaq Hashmi (ORCID: https://orcid.org/0009-0006-6355-3907)
- Marat Fudim
- Raheel Ahmed
- Gregg C. Fonarow
- Robert J Mentz
- Stephen J Greene
Institutions
- Kaiser Permanente (US)
- University of California, Los Angeles (US)
- Rawalpindi Medical University (PK)
- Dow University of Health Sciences (PK)
- Clinical Research Institute (US)
- Royal Brompton Hospital (GB)
- Lung Institute (US)
- Duke Medical Center (US)
- Imperial College London (GB)
Publication Details
- Journal
- ESC Heart Failure
- Published
- 2026-01-06
- DOI
- https://doi.org/10.1093/eschf/xvaf018
- Citations
- 1
- Primary Topic
- Erythropoietin and Anemia Treatment
- Type
- article
- Field-Weighted Citation Impact
- 35.41